Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

Overview of attention for article published in Orphanet Journal of Rare Diseases, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 1 news outlet

twitter: 7 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 35 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 12 X posts from 7 X users, with an upper bound of 6,099 followers.

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency | Orphanet Journal of Rare Diseases | Full Text https://t.co/e2lHvugnFQ

16 Jun 2022

Reply Repost Favourite

RT @RhythmPharma: Thank you, Dr. Mallya, for your continued impact both at Rhythm and in the broader rare #genetic diseases of #obesity com…

25 Apr 2022

Reply Repost Favourite

Thank you, Dr. Mallya, for your continued impact both at Rhythm and in the broader rare #genetic diseases of #obesity community. Click the below links to read the full studies – @Orphanet: https://t.co/y3ZrzrSP3S @AdvancesTherapy: https://t.co/91sYSgnPdF

25 Apr 2022

Reply Repost Favourite

Waiting patiently, or not so patiently for Nate to get on this medication. It will be life saving! It needs to happen!! It needed to happen years ago! https://t.co/R1QfuxF2zI

23 Apr 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.